M I Calvo1, R Y Cavero2. 1. Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Navarra, Irunlarrea s/n, 31008 Pamplona, Spain. Electronic address: mcalvo@unav.es. 2. Department of Environmental Biology, Faculty of Sciences, University of Navarra, Irunlarrea s/n, 31008 Pamplona, Spain.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: This paper provides significant ethnopharmacological information on plants used to treat cardiovascular diseases in Navarra, Spain. MATERIAL AND METHODS: Information was collected using semi-structured ethnobotanical interviews with 667 informants (mean age 72; 55.47% women, 44.53% men) in 265 locations. Official sources such as the European Scientific Cooperative on Phytotherapy (ESCOP), German Commission E, World Health Organization (WHO), European Medicines Agency (EMA), European Pharmacopoeia (Ph. Eur.) and Real Farmacopea Española (RFE) monographs were consulted in order to establish the therapeutic efficacy of the reported uses and to obtain further details about quality and safety aspects. A literature review was carried out on the plants that were most frequently cited and were not the subject of a monograph, using a new tool developed by the University of Navarra, UNIKA. RESULTS: A total of 460 pharmaceutical uses were reported by the informants, belonging to 90 plant species and 39 families, mainly represented by Urticaceae, Rosaceae, Asteraceae, and Equisetaceae. The most frequently used parts of the plants were the aerial parts followed by leaves and flowers. Seventeen out of 90 plants (19%) and 208 out of 460 popular uses (45%) had already been pharmacologically validated in relation to their therapeutic efficacy and safety aspects. CONCLUSIONS: The authors propose to validate five species for their use in cardiovascular diseases: Rhamnus alaternus L., Potentilla reptans L., Equisetum telmateia Ehrh., Centaurium erythraea Rafn and Parietaria judaica L.
ETHNOPHARMACOLOGICAL RELEVANCE: This paper provides significant ethnopharmacological information on plants used to treat cardiovascular diseases in Navarra, Spain. MATERIAL AND METHODS: Information was collected using semi-structured ethnobotanical interviews with 667 informants (mean age 72; 55.47% women, 44.53% men) in 265 locations. Official sources such as the European Scientific Cooperative on Phytotherapy (ESCOP), German Commission E, World Health Organization (WHO), European Medicines Agency (EMA), European Pharmacopoeia (Ph. Eur.) and Real Farmacopea Española (RFE) monographs were consulted in order to establish the therapeutic efficacy of the reported uses and to obtain further details about quality and safety aspects. A literature review was carried out on the plants that were most frequently cited and were not the subject of a monograph, using a new tool developed by the University of Navarra, UNIKA. RESULTS: A total of 460 pharmaceutical uses were reported by the informants, belonging to 90 plant species and 39 families, mainly represented by Urticaceae, Rosaceae, Asteraceae, and Equisetaceae. The most frequently used parts of the plants were the aerial parts followed by leaves and flowers. Seventeen out of 90 plants (19%) and 208 out of 460 popular uses (45%) had already been pharmacologically validated in relation to their therapeutic efficacy and safety aspects. CONCLUSIONS: The authors propose to validate five species for their use in cardiovascular diseases: Rhamnus alaternus L., Potentilla reptans L., Equisetum telmateia Ehrh., Centaurium erythraea Rafn and Parietaria judaica L.
Authors: Anna Marchelak; Aleksandra Owczarek; Magdalena Matczak; Adam Pawlak; Joanna Kolodziejczyk-Czepas; Pawel Nowak; Monika A Olszewska Journal: Front Pharmacol Date: 2017-10-11 Impact factor: 5.810
Authors: Gizem Emre; Ahmet Dogan; Mehmet Zeki Haznedaroglu; Ismail Senkardes; Mahmut Ulger; Aysen Satiroglu; Berivan Can Emmez; Osman Tugay Journal: Front Pharmacol Date: 2021-07-07 Impact factor: 5.810